Wellington Shields Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.01M Buy
16,603
+4,105
+33% +$239K 0.15% 102
2025
Q4
$674K Buy
12,498
+7,006
+128% +$337K 0.1% 132
2025
Q3
$248K Buy
5,492
+6
+0.1% +$280 0.04% 221
2025
Q2
$254K Buy
5,486
+272
+5% +$13.4K 0.04% 212
2025
Q1
$318K Sell
5,214
-2,536
-33% -$148K 0.06% 180
2024
Q4
$438K Buy
7,750
+4
+0.1% +$223 0.08% 160
2024
Q3
$401K Buy
7,746
+5
+0.1% +$235 0.07% 178
2024
Q2
$321K Buy
7,741
+341
+5% +$15.3K 0.06% 193
2024
Q1
$401K Sell
7,400
-1,191
-14% -$60.7K 0.08% 167
2023
Q4
$441K Sell
8,591
-153
-2% -$8.03K 0.06% 156
2023
Q3
$507K Buy
8,744
+2
+0% +$123 0.07% 135
2023
Q2
$559K Sell
8,742
-174
-2% -$11.7K 0.07% 140
2023
Q1
$618K Buy
8,916
+1
+0% +$71 0.07% 131
2022
Q4
$641K Buy
8,915
+1
+0% +$75 0.08% 124
2022
Q3
$634K Buy
8,914
+1
+0% +$73 0.15% 121
2022
Q2
$686K Sell
8,913
-295
-3% -$22.5K 0.09% 121
2022
Q1
$687K Sell
9,208
-21,453
-70% -$1.44M 0.08% 149
2021
Q4
$1.91M Buy
30,661
+15,001
+96% +$880K 0.24% 89
2021
Q3
$927K Sell
15,660
-19,298
-55% -$1.27M 0.13% 130
2021
Q2
$2.34M Sell
34,958
-3,843
-10% -$251K 0.28% 78
2021
Q1
$2.45M Sell
38,801
-829
-2% -$51.6K 0.23% 89
2020
Q4
$2.46M Buy
39,630
+8,656
+28% +$532K 0.33% 65
2020
Q3
$1.87M Sell
30,974
-3,016
-9% -$182K 0.3% 67
2020
Q2
$2M Sell
33,990
-2,838
-8% -$170K 0.32% 65
2020
Q1
$2.05M Buy
36,828
+1,488
+4% +$90.9K 0.39% 60
2019
Q4
$2.27M Buy
35,340
+3,500
+11% +$200K 0.35% 69
2019
Q3
$1.61M Buy
31,840
+400
+1% +$18.8K 0.26% 82
2019
Q2
$1.43M Sell
31,440
-1,253
-4% -$58.4K 0.24% 91
2019
Q1
$1.56M Sell
32,693
-150
-0.5% -$7.47K 0.27% 82
2018
Q4
$1.71M Sell
32,843
-2,347
-7% -$126K 0.32% 72
2018
Q3
$2.19M Sell
35,190
-300
-0.8% -$17.8K 0.35% 67
2018
Q2
$1.96M Sell
35,490
-5,540
-14% -$299K 0.32% 67
2018
Q1
$2.6M Buy
41,030
+1,530
+4% +$98.4K 0.39% 58
2017
Q4
$2.42M Sell
39,500
-2,100
-5% -$131K 0.38% 56
2017
Q3
$2.65M Sell
41,600
-138
-0.3% -$8.06K 0.44% 51
2017
Q2
$2.33M Sell
41,738
-99
-0.2% -$5.39K 0.38% 59
2017
Q1
$2.27M Sell
41,837
-13,900
-25% -$762K 0.37% 63
2016
Q4
$3.26M Buy
55,737
+6,902
+14% +$377K 0.54% 39
2016
Q3
$2.63M Sell
48,835
-13,289
-21% -$854K 0.46% 51
2016
Q2
$4.57M Buy
62,124
+3,605
+6% +$255K 0.77% 23
2016
Q1
$3.74M Sell
58,519
-2,663
-4% -$168K 0.65% 31
2015
Q4
$4.21M Sell
61,182
-897
-1% -$59.3K 0.71% 25
2015
Q3
$3.67M Sell
62,079
-24,746
-29% -$1.57M 0.63% 30
2015
Q2
$5.78M Buy
86,825
+204
+0.2% +$13.4K 0.88% 18
2015
Q1
$5.59M Buy
86,621
+1,153
+1% +$72.2K 0.84% 19
2014
Q4
$5.04M Sell
85,468
-1,196
-1% -$67.4K 0.8% 23
2014
Q3
$4.43M Sell
86,664
-1,995
-2% -$99.7K 0.74% 22
2014
Q2
$4.3M Sell
88,659
-596
-0.7% -$29.4K 0.67% 24
2014
Q1
$4.64M Buy
89,255
+505
+0.6% +$26.9K 0.79% 19
2013
Q4
$4.72M Buy
88,750
+4
+0% +$204 0.85% 17
2013
Q3
$4.11M Buy
88,746
+155
+0.2% +$6.8K 0.79% 16
2013
Q2
$3.96M Buy
+88,591
New +$3.85M 0.7% 19

Other funds holding BMY

Wellington Shields Capital Management's BMY Position: Q1 2026 in Review

Wellington Shields Capital Management increased its Bristol-Myers Squibb (BMY) stake by 33% in Q1 2026, buying an estimated $239K and bringing the position to 16,603 shares worth $1.01M. The position accounts for 0.15% of the portfolio, ranked #102.

Wellington Shields Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.78M in Q2 2015. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Wellington Shields Capital Management held 16,603 shares of Bristol-Myers Squibb worth $1.01M as of Q1 2026.
  • Wellington Shields Capital Management bought 4,105 Bristol-Myers Squibb shares in Q1 2026, an estimated $239K.
  • Bristol-Myers Squibb made up 0.15% of Wellington Shields Capital Management's portfolio in Q1 2026, its #102 holding.
  • Wellington Shields Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Wellington Shields Capital Management's Bristol-Myers Squibb position peaked at $5.78M in Q2 2015.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Wellington Shields Capital Management's 13F filing for Q1 2026, filed 4 May 2026.